Argenx Se Stock Price, News & Analysis

argenx (NASDAQ:ARGX) reported new VYVGART data at AANEM and MGFA (Oct 29–Nov 1, 2025) showing efficacy across generalized myasthenia gravis (gMG) populations.

Key findings: Phase 3 ADAPT SERON met its primary endpoint (p=0.0068) with a mean MG-ADL improvement of 3.35 at Week 4 in AChR‑Ab seronegative patients; ADAPT‑SC+ long‑term data showed 59.2% achieved minimal symptom expression (MSE) and 88.1% of responders sustained MSE ≥4 weeks; real‑world analysis reported 72.5% of patients tapered steroids and mean daily glucocorticoid dose fell from 16.6 to 7.5 mg at 18 months. No new safety signals were identified.

argenx (Euronext & Nasdaq: ARGX) will report third quarter 2025 financial results and provide a business update via a conference call and audio webcast on Thursday, October 30, 2025 at 1:30 PM CET (8:30 AM ET).

Investors can access the live webcast and a replay (available for ~one year) on the company's Investors website at argenx.com/investors. Dial‑in access is available across multiple countries using access code 3810049; participants are asked to dial in 15 minutes before the call.

argenx (NASDAQ:ARGX) will present more than 40 abstracts at the 2025 AANEM Annual Meeting and MGFA Scientific Session (Oct 29–Nov 1, 2025) covering VYVGART (IV and SC/Hytrulo) and pipeline candidate empasiprubart.

Key highlights include pivotal ADAPT SERON results showing clinically meaningful improvements with VYVGART in anti-AChR antibody–negative generalized myasthenia gravis across triple negative, MuSK, and LRP4 subtypes; interim ADAPT Jr data in juvenile gMG; long-term and real-world evidence for sustained benefit; and Phase 2/3 programs for empasiprubart in CIDP and MMN (EMVIGORATE, EMNERGIZE, EMPASSION).

argenx (Euronext & Nasdaq: ARGX) announced an Extraordinary General Meeting for shareholders on 18 November 2025 at 14:00 CET at Freshfields offices, Strawinskylaan 10, Amsterdam.

The meeting will consider the proposed adoption of a revised remuneration policy. The formal convocation includes details on in-person attendance, proxy voting, registration requirements and the e-voting system. All meeting documents and the agenda are available on argenx.com and abnamro.com/evoting, and may be inspected at argenx offices or requested by emailing legal@argenx.com. Shareholders are encouraged to vote by electronic proxy as described in the convocation.

argenx (Nasdaq: ARGX), a global immunology company, has announced its management team's participation in two upcoming investor conferences in September 2025. The company will present at the 2025 Wells Fargo Healthcare Conference on September 4 at 8:00 a.m. ET in Boston, and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8 at 7:00 a.m. ET in New York.

Investors can access live webcasts of both presentations through the Investors section of argenx's website, with replays available for approximately 30 days after each event.

argenx (NASDAQ:ARGX) announced positive topline results from its ADAPT SERON phase 3 study of VYVGART® in AChR-Ab seronegative generalized myasthenia gravis (gMG) patients. The study achieved its primary endpoint with statistical significance (p=0.0068), demonstrating meaningful improvements in patients' daily living activities compared to placebo.

This marks the first global phase 3 study showing clinical benefits across all three seronegative subtypes: MuSK+, LRP4+, and triple seronegative. The company plans to submit a Supplemental Biologics License Application (sBLA) to the FDA by the end of 2025 to expand VYVGART's label. The drug maintained its established safety profile with no new concerns identified.

argenx (Nasdaq: ARGX) announced an upcoming R&D webinar focusing on their ARGX-119 program, scheduled for September 16, 2025, at 2:00pm ET. The event, titled "R&D Spotlight | Pioneering MuSK Biology with ARGX-119," marks the first in a mini-series highlighting the company's pipeline and R&D strategy.

The webinar will feature argenx management, scientific leadership, and key opinion leaders discussing the MuSK agonist program and its potential applications in treating neuromuscular diseases, including congenital myasthenic syndromes (CMS), amyotrophic lateral sclerosis (ALS), and spinal muscular atrophy (SMA). The presentation will be accessible through the company's investor relations website.

argenx (Nasdaq: ARGX) has announced a partnership with nine-time Grand Slam champion Monica Seles to raise awareness for myasthenia gravis (MG). For the first time, Seles is publicly sharing her 5-year journey with MG, a chronic autoimmune disease affecting over 120,000 people in the U.S.

The partnership will highlight the company's 'Go for Greater' MG patient support initiative at the 2025 U.S. Open Tennis Championships, where argenx serves as a premier Global sponsor. The initiative aims to connect MG patients with support resources and foster community engagement through the website mg-united.com.

argenx (NASDAQ:ARGX) reported strong Q2 2025 financial results, with global product net sales reaching $949 million, representing 97% year-over-year growth. The company achieved $245 million in quarterly profit, with earnings per share of $4.02.

VYVGART SC launch in CIDP has gained momentum with over 2,500 patients on treatment globally. The company announced positive proof-of-concept data for ARGX-119 in CMS, advancing to a registrational study. argenx maintains its Vision 2030 goal of treating 50,000 patients globally, securing 10 labeled indications, and advancing five pipeline candidates to Phase 3.

The company's R&D and SG&A guidance remains at $2.5 billion, with six registrational and six proof-of-concept readouts expected by end of 2026.